Ipsen (OTCMKTS:IPSEY) Shares Pass Above Two Hundred Day Moving Average of $26.27

Ipsen S.A. (OTCMKTS:IPSEY – Get Rating) shares passed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $26.27 and traded as high as $27.47. Ipsen shares last traded at $27.45, with a volume of 1,059 shares traded.

Analyst Ratings Changes

IPSEY has been the subject of a number of research reports. Jefferies Financial Group initiated coverage on shares of Ipsen in a research report on Friday, December 2nd. They set a “buy” rating for the company. Barclays restated an “equal weight” rating on shares of Ipsen in a research report on Tuesday, December 6th. Deutsche Bank Aktiengesellschaft increased their price objective on shares of Ipsen from €90.00 ($96.77) to €95.00 ($102.15) and gave the company a “hold” rating in a research report on Thursday, January 12th. JPMorgan Chase & Co. increased their target price on shares of Ipsen from C$91.00 to C$115.00 in a research note on Monday, November 21st. Finally, Morgan Stanley raised shares of Ipsen from an “underweight” rating to an “equal weight” rating in a research note on Thursday, February 16th. Nine investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, Ipsen presently has an average rating of “Hold” and an average price target of $106.00.

Ipsen Stock Down 3.8 %

The company’s 50 day moving average is $27.76 and its 200 day moving average is $26.27.

Ipsen Company Profile

(Get Rating)

Ipsen SA engages in the manufacture of pharmaceutical products for oncology, neuroscience and rare diseases. It focuses on Oncology with Somatuline, a somatostatin analog for the treatment of neuroendocrine tumors; Cabometyx, the single-agent treatment with significant improvement across all key efficacy endpoints in second-line renal cell carcinoma; Onivyde, a differentiated product with overall survival benefit addressing a high unmet medical need in pancreatic cancer; and Decapeptyl, an established and growing product in Europe and China for prostate cancer and Rare Diseases with Nutropin, a liquid formulation of recombinant human growth hormone and Increlex, a recombinant insulin-like growth factor of human origin.